Many countries continue to struggle in procuring HIV drugs at affordable prices despite great progress in reducing the cost of medications, U.N. AIDS Executive Director Michel Sidibe writes. The great majority of patients in developing countries face prohibitive prices for second- and third-line treatments, which are needed in case of resistance to initial treatments, he writes. Balancing intellectual property rights with public health considerations is important to allow the developing world to manufacture high-quality drugs and boost their negotiating power with drugmakers, Sidibe writes. In separate articles, Black AIDS Institute leader Phill Wilson says that an end to the AIDS epidemic is possible without a cure but a lack of access to health care is a crucial obstacle, and epidemiology professor Myron S. Cohen says that a strong commitment is needed to research that could result in a vaccine.
Published in Brief: